AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Quantum Genomics Capital/Financing Update 2014

Dec 8, 2014

1617_iss_2014-12-08_97958f18-2b87-493b-bef0-95dc9f83219a.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

{# SEO P0-1: filing HTML is rendered server-side so Googlebot sees the full text without executing JS or following an iframe to a Disallow'd CDN path. The content has already been sanitized through filings.seo.sanitize_filing_html. #}

Massy - December 8, 2014

Quantum Genomics receives a 3 M€ financing

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, announces today that it received a medium-term financing of 3 M€, through a bond issue.

This strengthens the cash position of the company at a time when Quantum Genomics is very close to launch its phase II clinical trials of QGC001, first in class drug candidate for the treatment of hypertension (read the press release of November 17, 2014: Quantum Genomics receives all regulatory approvals to start its Phase II clinical trial in hypertension).

About Quantum Genomics

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.

Quantum Genomics is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than twenty years of academic research that has taken place in the laboratories of the Collège de France, INSERM and CNRS.

Quantum Genomics is listed on Alternext in Paris (ISIN code: FR0011648971 - ticker ALQGC).

Contacts

Quantum Genomics	Quantum Genomics	ACTUS
Lionel Ségard	Marc Karako	Jean-Michel Marmillon
CEO	CFO - Investor relations	Press relations
(+33) 1 60 13 76 80	(+33) 1 60 13 76 84	(33) 1 53 67 07 80
	[email protected]	[email protected]